PGxAI Named a Key Player in Straits Research’s Pharmacogenomics (PGX) Market Report

PALO ALTO, Calif., Sep. 22, 2025 - PGxAI has been recognized by Straits Research in its latest Pharmacogenomics (PGX) Market Size, Share & Trends Analysis Report (2025-2033), where the company is listed among the key market players and profiled as an emerging innovator in AI-driven pharmacogenomics.

According to the report, the global pharmacogenomics market was valued at $6.13B in 2024 and is projected to reach $11.17B by 2033 at a 6.6% CAGR-underscoring accelerating adoption of AI, bioinformatics, and EHR-integrated decision support across clinical workflows.

“We’re honored to be included by Straits Research as part of the industry’s leading cohort,” said Dr. Mike Zack, co-founder and CEO of PGxAI. “This recognition reflects our focus on turning complex genomic and clinical evidence into precise, point-of-care recommendations that help clinicians reduce adverse drug reactions and improve outcomes.”

Straits Research highlights the growing role of AI/ML-enabled platforms in scaling pharmacogenomic insights and improving turnaround time for guideline-concordant prescribing-areas central to PGxAI’s product roadmap and health-system integrations.

About PGxAI
PGxAI is an AI-driven precision-medicine company that transforms multi-omics and clinical data into real-time, gene-guided prescribing support for health systems, payors, and life sciences partners.